Inebilizumab-cdon (Uplizna)
Clinical policy defining medical necessity criteria, initial and continued approval, contraindications, dosing, and coding for inebilizumab-cdon (Uplizna) for NMOSD (AQP4+ adults) and IgG4-related disease in adults across Commercial, HIM, and Medicaid lines of business.
Added Epysqli to the list of therapies that Uplizna should not be prescribed concurrently with for NMOSD.
Revised continued approval duration from 6 to 12 months for NMOSD.
Added criteria for the newly approved indication of IgG4-RD.
Added step therapy bypass for IL HIM per IL HB 5395.
Added Bkemv and Ultomiris to the list of therapies that Uplizna should not be prescribed concurrently with.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.